Shaji Kumar

Experts Shaji Kumar and Naresh Bumma discuss selecting maintenance therapies post-ASCT for high-risk MM. They debate lenalidomide monotherapy vs. combination therapy with a proteosome inhibitor, the challenges of defining high-risk populations, and the need for prospective trials. Kumar and Bumma share their management strategies and highlight the future of managing high-risk MM post-ASCT.

Experts Shaji Kumar, Elena Zamagni, and Bruno Paiva discuss novel technologies for risk stratification in smoldering myeloma. They explore AI-driven early intervention and advancements in treating smoldering myeloma, emphasizing patient-focused therapy decisions and effective screening strategies.

Experts Shaji Kumar and Ashutosh Wechalekar discuss highlights from the ISA 2022 meeting, including diagnostic approaches in AL amyloidosis, advances in imaging techniques, and the role of stem cell transplantation in the era of daratumumab-based therapies.